Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
about
Dendritic cell vaccines for brain tumorsCheckpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous SystemStratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brainDiffuse glioma growth: a guerilla warDC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas.Challenges in clinical design of immunotherapy trials for malignant glioma.Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapyBrain Tumor Immunotherapy: What have We Learned so Far?Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects.Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.Selective cancer-germline gene expression in pediatric brain tumorsExploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators.Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironmentRegulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.Resection and Immunotherapy for Recurrent Grade III Glioma
P2860
Q24641823-A031A9C9-5C38-452F-AE45-1DD3E0A2E116Q28066906-95644967-18C6-4D63-98A7-11AAAC07715AQ34260758-5EC96B97-AB1F-4328-B5AF-44BF26E23157Q35799695-FFFEE276-28ED-4167-BF7F-DC91758B058CQ36283733-9F11A885-78D7-4AE4-BC3E-4AAE5E62E3EDQ36931690-300451DE-2635-4917-A982-D062E59541F6Q37395354-402F1CA1-C354-4DE1-BD19-94189E2B5805Q37517954-0024F526-6E1A-4719-8F63-719A38B83220Q37640613-CEEB3E4E-CB68-4897-B7CB-C7304B9B058CQ37734481-A896E5D1-E6E1-48BE-9AB4-490BD2CA7D08Q38542113-B7FA9DB7-B5D0-4772-8ECD-10CC1BB9B74CQ38912265-78F205B8-C477-4616-B60C-DFF6F384306CQ39408982-7D85D07F-213D-4015-9D64-4FC424E8F94AQ39500714-CFE2CDB3-024F-449D-84E7-5B2B6CBA12D0Q39609814-27124D2E-32F5-4782-882F-656E2985B356Q40847481-3A3FA8B8-AB72-4A28-8EA3-68C3FEFA9764Q42426009-EBB6CEDD-2FC6-4E5D-BA11-C4448F2286F0Q42554303-2595935E-9CEE-4A8C-9874-ABFB2115CDC0Q58691159-08332183-FBA5-4C8C-8BEB-81B5F85BC397
P2860
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Dendritic cell vaccination in ...... status and future directions.
@ast
Dendritic cell vaccination in ...... status and future directions.
@en
type
label
Dendritic cell vaccination in ...... status and future directions.
@ast
Dendritic cell vaccination in ...... status and future directions.
@en
prefLabel
Dendritic cell vaccination in ...... status and future directions.
@ast
Dendritic cell vaccination in ...... status and future directions.
@en
P2093
P1433
P1476
Dendritic cell vaccination in ...... t status and future directions
@en
P2093
Hans-Jakob Steiger
Marion Rapp
Michael Sabel
Rüdiger V Sorg
Stefaan van Gool
Walter Stummer
P304
988-99; discussioin 999-1000
P356
10.1227/01.NEU.0000245595.38957.3E
P407
P577
2006-11-01T00:00:00Z